EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

The Effect of Metformin on Insulin Requirement, Glycaemic Control and Weight Gain in Type 1 Diabetes During Pregnancy—a Randomised, Placebo‐Controlled Multicentre Study

Elina Juuma iD, Kati Tihtonen, Saara E Metso, Päivi M Hannula, Mika Helminen, Kristiina Tertti, Heidi Immonen, Leena Georgiadis, Kirsi Väyrynen, Petteri Ahtiainen, Hilkka Nikkinen, Minna Koivikko und 2 weitere

Diabetes/Metabolism Research and Reviews · 2025

DOI: 10.1002/dmrr.70085 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Elina Juuma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 1, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: State research funding, Wellbeing Services County of North Savo, State research funding, Wellbeing Services County of Pirkanmaa, Hilja and Onni Tuovinen Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Our aim was to ascertain whether metformin can reduce insulin requirement without compromising glycaemic control during pregnancy in women with type 1 diabetes.

Methods

A total of 126 pregnant women with type 1 diabetes were recruited for a randomised, double‐blind, placebo‐controlled multicentre study. The primary outcome was total insulin change, defined as the difference between baseline and third trimester maximum insulin dose (IU).

Results

Fifty women in the placebo group and 51 women in the metformin group completed the study. A predetermined sample size of 200 participants was not achieved. There was no significant difference in the primary outcome, that is, in the change of total insulin requirement (33 vs. 27 IU, p = 0.193). However, the metformin group showed a significantly lower increase in the prandial insulin change, with 24 versus 14 IU ( p = 0.014) and 0.3 versus 0.2 IU/kg ( p = 0.048). In the exploratory subgroup analysis, metformin attenuated prandial insulin increase in women with high BMI (> 25 kg/m 2 ) or high baseline insulin requirement (> 40 IU) (25 vs. 15 IU, p = 0.028, 30 vs. 14 IU, p = 0.007). Weight gain remained more often within target in the metformin group (20% vs. 40%, p = 0.029). A similar weight benefit was observed in subgroups (BMI> 25 kg/m 2 8% vs. 32%, p = 0.005, insulin requirement> 40 IU 6% vs. 34%, p = 0.004). No differences were seen in glycaemic control or neonatal outcome between the groups.

Conclusions

Metformin was not shown to affect total insulin change but reduced the prandial insulin change and improved weight gain control especially in insulin‐resistant subgroups. These findings warrant further studies on metformin as an adjunctive medicine. Trial Registration ClinicalTrials.gov: NCT03765359.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 1Hypoglycemic AgentsInsulinGlycemic ControlPregnancy in DiabeticsWeight GainHumansFemalePregnancyAdultDouble-Blind MethodBlood GlucoseFollow-Up StudiesPrognosisGlycated HemoglobinYoung AdultBiomarkers

Stichwörter der Autor:innen

diabetes type 1insulin resistancemetforminplacebopregnancy

Substanzen

MetforminHypoglycemic AgentsInsulinBlood GlucoseGlycated HemoglobinBiomarkershemoglobin A1c protein, human

Autor:innen und Institutionen

  • Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Department of Obstetrics and Gynecology, Wellbeing Services County of Central Finland, Jyväskylä, Finland.
  • Department of Obstetrics and Gynecology, Wellbeing Services County of Pirkanmaa, Tampere University Hospital, Tampere, Finland.
  • Department of Internal Medicine, Wellbeing Services County of Pirkanmaa, Tampere University Hospital, Tampere, Finland.
  • Tays Research Services, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Tampere, Finland.
  • Faculty of Social Sciences, Health Sciences, Tampere University, Tampere, Finland.

ORCID-Profile: Elina Juuma

Förderung

  • State research funding, Wellbeing Services County of North Savo
  • State research funding, Wellbeing Services County of Pirkanmaa
  • Hilja and Onni Tuovinen Foundation
  • Finnish Medical Foundation
  • Orion Research Foundation
  • Jalmari and Rauha Ahokas Foundation
  • Instrumentarium Science Foundation
  • Tampere University Hospital Support Foundation

Zitieren

APA

Juuma, E., Tihtonen, K., Metso, S. E., Hannula, P. M., Helminen, M., Tertti, K., Immonen, H., Georgiadis, L., Väyrynen, K., Ahtiainen, P., Nikkinen, H., Koivikko, M., Laivuori, H., & Uotila, J. (2025). The Effect of Metformin on Insulin Requirement, Glycaemic Control and Weight Gain in Type 1 Diabetes During Pregnancy—a Randomised, Placebo‐Controlled Multicentre Study. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70085

Vancouver

Juuma E, Tihtonen K, Metso SE, Hannula PM, Helminen M, Tertti K, et al. The Effect of Metformin on Insulin Requirement, Glycaemic Control and Weight Gain in Type 1 Diabetes During Pregnancy—a Randomised, Placebo‐Controlled Multicentre Study. Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70085

BibTeX
@article{Juuma2025,
  author = {Juuma, Elina and Tihtonen, Kati and Metso, Saara E and Hannula, Päivi M and Helminen, Mika and Tertti, Kristiina and Immonen, Heidi and Georgiadis, Leena and Väyrynen, Kirsi and Ahtiainen, Petteri and Nikkinen, Hilkka and Koivikko, Minna and Laivuori, Hannele and Uotila, Jukka},
  title = {The Effect of Metformin on Insulin Requirement, Glycaemic Control and Weight Gain in Type 1 Diabetes During Pregnancy—a Randomised, Placebo‐Controlled Multicentre Study},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2025},
  doi = {10.1002/dmrr.70085}
}
Kostenlos starten →